Showing results (151-160 of 161) with videos related to
Sort By:
Pageof 17
Journal of the National Cancer Institute|April 19, 1989
Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerationsW J Urba, J W Clark, R G Steis, et al.Cancer Research|April 1, 1989
Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanomaR L Miller, R G Steis, J W Clark, et al.Cancer|January 5, 2000
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumorsD P Ryan, T J Lynch, M L Grossbard, et al.Journal of the National Cancer Institute|April 18, 1990
Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trialR G Steis, L A VanderMolen, D L Longo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavityR G Steis, W J Urba, L A VanderMolen, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLCS-H I Ou, P A Jänne, C H Bartlett, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2009
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancerP C Enzinger, D P Ryan, J W Clark, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancerL S Blaszkowsky, D P Ryan, J Szymonifka, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 14, 2019
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001A T Shaw, G J Riely, Y-J Bang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycleA L Hamilton, J P Eder, A C Pavlick, et al.Pageof 17